Lexaria raises $2M via registered direct offering of common stock and pre-funded warrants

Lexaria Bioscience Corp.

Gross proceeds $2M from sale of 2M shares/pre-funded warrants at $1.00 per share to one institutional investor.
No new warrants issued to investor other than pre-funded warrants; placement agent gets 70,000 warrants at $1.25.
Offering closed April 28, 2025; net proceeds for working capital and general corporate purposes.
CEO states transaction minimized dilution during uncertain market; H.C. Wainwright acted as exclusive placement agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.